| Not Yet Recruiting | Evaluation of the Efficacy and Safety of Magnetic Resonance Angiography (MRA) Using Gadopiclenol Compared to G Steno-occlusive Disease | Phase 3 | 2026-02-02 |
| Completed | Performance of Elucirem in DSC-MRI Perfusion of Brain Gliomas Brain Tumor, Primary, Brain Tumor, Recurrent | Phase 3 | 2023-09-07 |
| Completed | Evaluation of Gadopiclenol for Magnetic Resonance Imaging (MRI) in Japanese Adults and Children Lesion in Body Region, CNS Lesion | Phase 3 | 2023-07-21 |
| Unknown | Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT Examina Patient Participation | — | 2022-10-01 |
| Completed | Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age Central Nervous System Diseases, Pediatric Disorder, Body Indication | Phase 2 | 2022-09-21 |
| Unknown | Safety and Performance of Vectorio® in Conventional Trans-Arterial Chemo-Embolization (cTACE): A Post-Market C Oncology | — | 2022-08-30 |
| Completed | Pharmacokinetics and Safety of Gadopiclenol in Japanese Healthy Volunteers Pharmacokinetics | Phase 1 | 2021-05-10 |
| Recruiting | Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magneti Motor Function, Cognitive Function, Contrast Media | Phase 4 | 2021-03-24 |
| Completed | Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) Lesion in Body Region | Phase 3 | 2019-08-27 |
| Completed | Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) CNS Lesion, Blood Brain Barrier Defect | Phase 3 | 2019-06-03 |
| Completed | Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contra Central Nervous System Indication, Pediatric Patients, Body Indication | Phase 2 | 2018-11-06 |
| Completed | A Study to Evaluate How Safe and Effective is the Mixture of Lipiodol® Ultra Fluid and Glue When Used for Embo Congenital Hemangioma, Hemangioendothelioma, Angiosarcoma | Phase 4 | 2017-11-29 |
| Completed | Pharmacokinetics, Dialysability and Safety of P03277 in Healthy Volunteers and in Patients With Impaired Renal Renal Insufficiency, Healthy Volunteers | Phase 1 | 2017-10-13 |
| Completed | Cardiac Safety Evaluation of P03277 Healthy Volunteers | Phase 1 | 2017-08-21 |
| Completed | Proof of Concept Study Concerning Efficacy of P03277 MR Imaging in HCC Diagnosis Chronic Liver Disease, HepatoCellular Carcinoma | Phase 2 | 2016-12-01 |
| Completed | P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) CNS Lesion, Blood Brain Barrier Defect | Phase 2 | 2016-06-01 |
| Completed | DOTAREM Pharmacokinetics and Safety Study in Pediatric Subjects Aged < 2 Years Magnetic Resonance Imaging | Phase 4 | 2015-03-01 |
| Completed | Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Primary Brain Tumor | Phase 4 | 2014-06-01 |
| Completed | Pharmacokinetics, Pharmacodynamics Profile and Tolerance of P03277 in Healthy Subjects and Patients With Brain Healthy Volunteers, Brain Lesion | Phase 1 / Phase 2 | 2013-11-25 |
| Terminated | DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC Hepatocellular Carcinoma | Phase 4 | 2013-05-09 |
| Completed | Hepatic Xenetix-CT Perfusion Hepatocellular Carcinoma | Phase 4 | 2012-04-01 |
| Completed | Safety and Dialysability of Dotarem® in Dialysed Patients End-stage Renal Failure | Phase 1 | 2011-11-01 |
| Completed | Post Marketing Surveillance Study for Evaluation of Efficacy and Safety of Dotarem in Magnetic Resonance Mammo MR Mammography With Dotarem | — | 2011-09-01 |
| Completed | Observational Study on the Incidence of NSF in Renal Impaired Patients Following Dotarem Administration Renal Insufficiency | — | 2011-05-01 |
| Completed | Post-marketing Surveillance Study for Evaluation of Dotarem Safety Contrast-enhanced MRI With Dotarem | — | 2011-01-01 |
| Completed | Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Coronary Artery Disease | Phase 4 | 2010-11-01 |
| Completed | Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions Diagnostic Self Evaluation, Central Nervous System Diseases | Phase 3 | 2010-09-01 |
| Completed | Assessment With CCTA and MRI in Asymptomatic Patients With Type 2 Diabetes for Detection of Unrecognized Myoca Type 2 Diabetes Mellitus, Coronary Atherosclerosis | Phase 4 | 2010-08-01 |
| Completed | Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease Peripheral Arterial Disease | Phase 4 | 2009-10-01 |
| Completed | Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) Cerebral Arterial Diseases | Phase 3 | 2009-10-01 |
| Completed | Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) Cerebral Arterial Diseases | Phase 3 | 2009-10-01 |
| Terminated | Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF) Renal Disease | Phase 3 | 2009-09-01 |
| Completed | DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Dis Peripheral Arterial Disease | Phase 4 | 2009-07-01 |
| Terminated | Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF) Renal Artery Stenosis | Phase 3 | 2009-04-01 |
| Withdrawn | Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK I Nephrogenic Systemic Fibrosis, Renal Insufficiency | — | 2009-02-01 |
| Terminated | Effects of Contrast Media on Subjects With Stable Reduced Renal Function Undergoing Contrast-Enhanced Computed Renal Impairment | Phase 4 | 2009-01-01 |
| Completed | Observational Post-marketing Study on the Safety and Efficacy of Dotarem® (SECURE Study) General Safety Profile of DOTAREM | — | 2008-11-01 |
| Completed | Renal Safety Evaluation After Dotarem®-Enhanced MRI Renal Insufficiency | Phase 4 | 2008-01-01 |
| Completed | A Clinical Study of Iobitridol in Patients Undergoing Multislice Computed Tomography (CT) Abdominal Angiograph Diagnostic Imaging | Phase 4 | 2006-08-01 |
| Completed | A Clinical Study of Xenetix 300 in Multislice Computed Tomography (CT) Pediatric Indications Diagnostic Imaging | Phase 4 | 2006-05-01 |
| Completed | A Clinical Study of Gadoteric Acid in Non-Coronary Magnetic Resonance (MR) Angiography Arterial Occlusive Disease | Phase 4 | 2006-03-01 |
| Completed | Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Optimark (Gadoversetamide) in Pediatric Patient Pathological Processes | Phase 4 | 2002-05-01 |